Literature DB >> 17341187

Role of cAMP phosphodiesterase 4 in regulation of T-cell function.

Elisa Bjørgo1, Kjetil Taskén.   

Abstract

Ligation of both the T-cell receptor (TCR) and the CD28 receptor is required for full T-cell activation to occur. Engagement of the TCR in primary T cells is followed by rapid cAMP production in lipid rafts resulting in raft-associated protein kinase A (PKA) activation and inhibition of proximal T-cell signaling. However, upon TCR and CD28 cross-ligation, beta-arrestin in complex with cAMP-specific phosphodiesterase 4 (PDE4) is recruited to lipid rafts, thus downregulating cAMP levels. Consequently, the activities of both PKA and PDE4 seem to be important for the regulation of TCR-induced signaling and T-cell function. We, therefore, propose a novel role for TCR and CD28 co-stimulation in the downmodulation of TCR-induced cAMP-mediated inhibitory signals through the recruitment of beta-arrestin and PDE4 to lipid rafts, thus allowing a full T-cell response to occur.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17341187     DOI: 10.1615/critrevimmunol.v26.i5.40

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  11 in total

Review 1.  Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology.

Authors:  Peter B Ernst; James C Garrison; Linda F Thompson
Journal:  J Immunol       Date:  2010-08-15       Impact factor: 5.422

2.  Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.

Authors:  Ying Tan; Amanda A Watkins; Benjamin B Freeman; John A Meyers; Ian R Rifkin; Adam Lerner
Journal:  J Immunol       Date:  2015-01-01       Impact factor: 5.422

3.  β-Arrestin 1 modulates functions of autoimmune T cells from primary biliary cirrhosis patients.

Authors:  Zhide Hu; Yuanlan Huang; Yang Liu; Yi Sun; Ye Zhou; Mingli Gu; Yan Chen; Rong Xia; Sunxiao Chen; Anmei Deng; Renqian Zhong
Journal:  J Clin Immunol       Date:  2011-01-18       Impact factor: 8.317

Review 4.  Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.

Authors:  Jeffrey D Cooney; Ricardo C T Aguiar
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113

5.  Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model.

Authors:  Ai-Xia Dou; Li-Li Feng; Xiao-Qian Liu; Xin Wang
Journal:  Cell Mol Immunol       Date:  2012-09-24       Impact factor: 11.530

6.  Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.

Authors:  Kevin Kelly; Alex Mejia; Avvaru N Suhasini; An-Ping Lin; John Kuhn; Anand B Karnad; Steven Weitman; Ricardo C T Aguiar
Journal:  Clin Cancer Res       Date:  2016-08-19       Impact factor: 12.531

Review 7.  β-Arrestins in the immune system.

Authors:  Dianhua Jiang; Ting Xie; Jiurong Liang; Paul W Noble
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

8.  East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease.

Authors:  Manju Sharma; Corey Levenson; John C Browning; Emily M Becker; Ian Clements; Paul Castella; Michael E Cox
Journal:  Front Pharmacol       Date:  2018-03-09       Impact factor: 5.810

Review 9.  Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units.

Authors:  Vanessa L Wehbi; Kjetil Taskén
Journal:  Front Immunol       Date:  2016-06-08       Impact factor: 7.561

10.  Beta-2 adrenergic receptors increase TREG cell suppression in an OVA-induced allergic asthma mouse model when mice are moderate aerobically exercised.

Authors:  Kari J Dugger; Taylor Chrisman; Sarah L Sayner; Parker Chastain; Kacie Watson; Robert Estes
Journal:  BMC Immunol       Date:  2018-02-17       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.